Navigation Links
Golub Capital Provides Debt Financing to Support the Acquisition of DNA Diagnostics Center, Inc. by MTS Health Investors, LLC
Date:10/21/2008

NEW YORK, Oct. 21 /PRNewswire/ -- Golub Capital today announced that it has provided a GOLD facility for the acquisition of DNA Diagnostics Center, Inc. (DDC) by MTS Health Investors, LLC (MTS). GOLD financings are proprietary Golub Capital One-Loan Debt facilities. Terms of the transaction were not disclosed.

DDC, based in Fairfield, Ohio, is one of the largest and most reputable DNA testing laboratories worldwide and the market leader in human DNA identification testing for the private sector. The Company provides a wide array of DNA testing services in the fields of biological family relationships, forensics and veterinary genetics.

DDC has achieved national recognition serving as the laboratory of choice for many national media programs including Dateline, 48 Hours and Dr. Phil, and has provided the DNA testing for numerous high-profile legal disputes. These cases include the Ohio Innocence Project, which helped exonerate Robert McClendon after 18 years of incarceration, and the landmark paternity suit that identified Larry Birkhead as the biological father of Anna Nicole Smith's daughter.

This is Golub Capital's first deal with MTS. "We are pleased to be working with MTS," said Golub Capital Principal Stefano Robertson. "Golub Capital's financial resources will help strengthen DDC's position in its unique marketplace. We are looking forward to watching DDC grow internationally."

"In this difficult economic environment it is terrific to have Golub Capital as a partner. Golub followed through with its commitment even during this volatile credit market. After working with the Golub team on closing this deal, we are confident that Golub will help us grow the company as we capitalize on opportunities within the DNA testing industry," says Kenton Rosenberry, a Managing Director with MTS.

About Golub Capital

Golub Capital underwrites and syndicates 1st lien loans up to $150 million. Our buy-and-hold products range from $5 million to $75 million and include one-loan financings (through the Firm's proprietary GOLD facility), senior, second lien and subordinated debt, preferred stock and co-investment equity. With a broad investment mandate and long-term time horizon, Golub Capital has a high level of flexibility in structuring investments. Golub Capital is a national firm. For more information, please visit http://www.golubcapital.com.


'/>"/>
SOURCE Golub Capital
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Simbionix Raises Largest Amount in Companys History in Venture Capital to Accelerate Growth
2. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
3. Solos Endoscopy, Inc. Implements Strategy to Capitalize on $30 Billion Minimally Invasive Surgical Product Market
4. CPC of America, Inc. to Explore Strategic Alternatives; Appoints FTI Capital Advisors to Assess Potential Opportunities
5. Aerolase Retains SMH Capital Inc. to Advise on Corporate Expansion
6. Tengion Featured as Model of Innovation and Success at 35th Anniversary Celebration of the National Venture Capital Association
7. Aegis Analytical Corp. Showcases Discoverant at Inaugural Venture Capital in the Rockies Fall
8. Sinobiomed Retains CB Capital Partners as Financial Advisor to Maximize Shareholder Value
9. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
10. TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm
11. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , Feb. 11, 2016  Vermillion, Inc. (NASDAQ: ... gynecologic disease, today announced the formation of the Steering ... --> --> Pelvic masses can ... diagnosis and management. Once pregnancy is ruled out, pelvic ... and ovaries, advanced endometriosis, benign ovarian tumors and gastrointestinal ...
(Date:2/11/2016)... , Germany and ... -- QGEN ; Frankfurt Prime Standard: QIA) ... QIAseq Targeted RNA Panels for gene expression profiling, expanding ... sequencing (NGS). The panels enable researchers to select from ... fold changes and discover interactions between genes, cellular phenotypes ...
(Date:2/11/2016)... -- Bioethics International, a not-for-profit organization focused on the ethics and ... accessible to patients around the world, today announced that the ... of the Good Pharma Scorecard an ,Editors, ... one of BMJ Open ,s ,Most Popular Articles, which ... frequently read. Ed Sucksmith , assistant editor of ...
(Date:2/11/2016)... , Feb. 11, 2016  Spectra BioPharma Selling Solutions ... that provides biopharma companies the experience, expertise, operational ... deploy outsourced sales teams. Created in concert with ... both the strategic and tactical needs of its ... solutions through both personal and non-personal promotion. ...
Breaking Biology Technology:
(Date:2/11/2016)... Feb. 11, 2016  Vigilant Solutions announces today that its ... being used by Lee,s Summit Police ... location and arrest of a homicide suspect. ... covers around 65 square miles and is home to roughly ... has a single mobile license plate reader system and also ...
(Date:2/10/2016)... , February 10, 2016 ... According to 2016 iris recognition market report, ... recognition is more widely accepted for border ... both fingerprint and iris recognition technology in ... to avoid purchasing two individual biometrics devices. ...
(Date:2/9/2016)... (NASDAQ: AWRE ), a leading supplier of biometrics software and ... ended December 31, 2015.  --> ... million, an increase of 61% compared to $4.3 million in the ... 2015 was $2.6 million compared to $0.2 million in the fourth ... Higher revenue and operating income in the fourth quarter of ...
Breaking Biology News(10 mins):